Medical methods for First trimester abortion upto 10weeks
- Registration Number
- CTRI/2022/01/039355
- Lead Sponsor
- SDM College of medical sciences and hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Suspended
- Sex
- Not specified
- Target Recruitment
- 0
Only women with a visible intrauterine gestational sac were enrolled. Mean sac diameter (length width depth/3) was used to determine estimated gestational age (EGA) only when an embryonic pole was absent. Last menstrual period was used to determine EGA if the last menstrual period was within 3 days of the ultrasound EGA; however, the ultrasound estimate was used if it differed by 4 days or more from the EGA by last menstrual period.
Potential subjects were EXCLUDED if they had any contraindication to mifepristone, including chronic systemic corticosteroid administration or adrenal disease; had any contraindications to misoprostol, including glaucoma, mitral stenosis, sickle cell anemia, poorly controlled seizure disorder, or known allergy to prostaglandin; had cardiovascular disease, including angina, valvular disease, arrhythmia, or cardiac failure; had a known coagulopathy or were receiving treatment with anticoagulants; had a pregnancy with an intrauterine device in utero; had active cervicitis on examination; if their ultrasound examination results demonstrated any evidence of an early pregnancy failure, had previously participated in the trial.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method to compare- complete abortion rates in women who received mifepristone followed by vaginal misoprostol 6 to 8 hours later (experimental group) and 24 hours later (standard care group) <br/ ><br>Timepoint: Complete abortion
- Secondary Outcome Measures
Name Time Method side effects, bleeding, and acceptabilityTimepoint: Side effects, bleeding and acceptability